Xenon Pharmaceuticals (XENE) Accumulated Depreciation & Amortization (2016 - 2025)
Xenon Pharmaceuticals (XENE) has disclosed Accumulated Depreciation & Amortization for 12 consecutive years, with $686000.0 as the latest value for Q4 2025.
- Quarterly Accumulated Depreciation & Amortization rose 174.97% to $686000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $686000.0 through Dec 2025, up 174.97% year-over-year, with the annual reading at $686000.0 for FY2025, 174.97% up from the prior year.
- Accumulated Depreciation & Amortization for Q4 2025 was $686000.0 at Xenon Pharmaceuticals, up from -$915000.0 in the prior quarter.
- The five-year high for Accumulated Depreciation & Amortization was $2.6 million in Q4 2021, with the low at -$5.3 million in Q4 2022.
- Average Accumulated Depreciation & Amortization over 5 years is -$700600.0, with a median of -$542000.0 recorded in 2023.
- The sharpest move saw Accumulated Depreciation & Amortization plummeted 306.93% in 2022, then surged 174.97% in 2025.
- Over 5 years, Accumulated Depreciation & Amortization stood at $2.6 million in 2021, then tumbled by 306.93% to -$5.3 million in 2022, then skyrocketed by 89.75% to -$542000.0 in 2023, then crashed by 68.82% to -$915000.0 in 2024, then soared by 174.97% to $686000.0 in 2025.
- According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $686000.0, -$915000.0, and -$542000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.